2026-04-17T03:20:32Zhttps://recercat.cat/oai/requestoai:recercat.cat:10230/331622026-03-20T16:27:17Zcom_2072_6col_2072_452952
RECERCAT
author
Deza Vargas, Luis Gustavo
author
Bertolín Colilla, Marta
author
Pujol Vallverdú, Ramón M.
author
Curto Barredo, Laia
author
Soto Soto, Dulce
author
García, Maribel
author
Hernández, Pilar
author
Gimeno Martínez, Ramón
author
Giménez Arnau, Anna Maria
2017-11-07T11:49:20Z2017-11-07T11:49:20Z2017
Although the efficacy of omalizumab has been clearly demonstrated in the treatment of chronic spontaneous urticaria (CSU), its mechanism of action, which results in improvement in CSU symptoms, is not entirely understood. This study investigated the effect of omalizumab on expression of the high-affinity IgE receptor (FcεRI) on blood basophils from patients with active CSU, and its association with the clinical response. Patients exhibiting significant clinical improvement showed a sharp reduction in the levels of basophil FcεRI after 4 weeks, which was maintained throughout the total duration of the treatment. Such evolution was not observed in non-responder patients. Furthermore, non-responders showed significantly lower baseline levels of FcεRI than responders. Baseline basophil FcεRI expression was found to be a potential immunological predictor of response to omalizumab (100% sensitivity and 73.2% specificity). The results of this study contribute to our knowledge of the therapeutic benefit and mechanism of action of anti-IgE therapy in CSU.
This is an open access article under the CC BY-NC license. www.medicaljournals.se/acta. Journal Compilation © 2017 Acta Dermato-Venereologica. http://creativecommons.org/licenses/by-nc/4.0/ info:eu-repo/semantics/openAccess
Urticaria
Basophil FcεRI expression in chronic spontaneous urticaria: A potential immunological predictor of response to omalizumab therapy.
info:eu-repo/semantics/article info:eu-repo/semantics/acceptedVersion